Loading data for ACIU — first visit, this takes a few seconds.
AC Immune SA (ACIU)
NasdaqGM: ACIU
· Real-Time Price · USD
2.88
-0.02 (-0.69%)
At close: Aug 28, 2026, 8:00 PM
2.65
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
AC Immune SA (ACIU) Stock Price, Analysis & Data
-0.69% (1D)
No data available
| Bid | 1.6 |
| Market Cap | 263.48M |
| Revenue (ttm) | 17.51M |
| Net Income (ttm) | -43.16M |
| 1.57 | |
| -0.54 | |
| n/a | |
| 4.3 | |
| P/B (ttm) | 6.03 |
| P/S (ttm) | 15.05 |
| Earnings Date | Nov 4, 2026 |
| Ask | 2.9 |
| Volume | 203,533 |
| Avg. Volume (20D) | 261,850 |
| Open | 2.91 |
| Previous Close | 2.90 |
| Day's Range | 2.80 - 2.99 |
| 52-Week Range | 2.03 - 4.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative dis...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2016
Employees 90
Stock Exchange NasdaqGM
Ticker Symbol ACIU
Website https://www.acimmune.com
Financial Performance
In 2025, AC Immune SA's revenue was 3.57M, a decrease of -86.92% compared to the previous year's 27.31M. Earnings were -70.45M, an increase of 38.36%.
Financial StatementsEarnings Surprise
AC Immune SA has released their quarterly earnings on Aug 5, 2026:
- Revenue of $15.11M misses estimates by $0, with 1057.20% YoY growth.
- EPS of 0.02 exceeds estimates by 0.13, with 109.52% YoY growth.
AC Immune SA is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2